How Restaurants Are Adapting to Health and Safety Regulations Worldwide

Lesbico Videos Porno(Porn website:777888sex.cc)pXAuConstruction Sector Embraces Eco-Friendly Materials to Meet Environmental Goals

**China's First Report on Multiple Sclerosis Patients Released** The Chinese Society of Neurology, in collaboration with the China Medical Promotion Association, released the country’s first "Multiple Sclerosis Patient Survival Report" yesterday. The research for this report was conducted by 49 Multiple Sclerosis (MS) treatment centers across China. Multiple Sclerosis is a rare disease that affects the central nervous system. It is estimated that there are about 30,000 MS patients in China. Professor Cui Liying, Chair of the Chinese Society of Neurology and Director of the Neurology Department at Peking Union Medical College Hospital, explained that the diagnosis process for MS is lengthy and challenging, with 38% of patients being misdiagnosed with other conditions. According to Professor Cui, the early symptoms of MS are complex and varied. "Some patients experience numbness in their limbs, while others may suffer from dizziness, hiccups, or intense itching. These symptoms are not specific to MS." On average, MS patients have at least one form of neurological disability, yet only 10% of them are using standard treatment drugs. These medications, which need to be taken long-term, can significantly reduce the frequency of relapses. "We urge all stakeholders to work together so that these essential treatment drugs can be included in national insurance, allowing more patients to access treatment." MS typically affects individuals between the ages of 20 and 40, which is the prime period of adulthood. Due to neurological damage, the most common clinical symptoms include sensory disturbances, motor impairments in the limbs, fatigue, and balance issues. Other symptoms may include vision loss, dizziness, double vision, pain, cognitive impairment, ataxia, and bladder or bowel dysfunction. The report also highlights a geographical disparity, with more MS cases in northern China, such as the northeastern regions, compared to the south. This trend is consistent with other countries, like Canada, where MS is not considered a rare disease due to its high prevalence. Patients with MS often experience progressive disability over time. Among those with relapsing-remitting MS, 50% may develop secondary progressive MS within an average of 6.6 years, severely impacting mobility. Patients with secondary progressive MS often have significant walking impairments, with an average walking distance of less than 100 meters. The report notes that in China, 47% of patients do not receive an immediate diagnosis, and 38% are misdiagnosed, commonly with conditions like neuromyelitis optica, anxiety, vascular diseases, or ophthalmological conditions. MS is a lifelong condition, and disease-modifying therapies during the remission phase are crucial for many patients, as they can effectively reduce the annual relapse rate and slow disability progression. However, China currently has only two available disease-modifying drugs, compared to 16 in Western countries. Public awareness remains low, with 95% of surveyed patients stating they had never heard of MS before their diagnosis. Experts suggest that Chinese patients enter the progressive stage of the disease earlier than Western patients, possibly due to insufficient treatment during the relapse phase and a lack of standardized care. The mental health burden on MS patients is also significant. Due to limited awareness and understanding of the disease, 84% of patients report experiencing negative emotions following their diagnosis. Between 15% and 18% of patients report deteriorating relationships with family and friends, and 13% have considered suicide. Professor Hu Xueqiang, Chair of the Neuroimmunology Branch of the Chinese Society of Immunology, emphasized the severe psychological toll, recalling three young MS patients who had committed suicide. "The financial burden is heavy, and the psychological pressure is immense," said Hu. MS has a profound impact on patients and their families, contributing to considerable economic and social burdens.